Dr. Falk Pharma announced its acquisition of Kynos Therapeutics, one of Riyadh Valley Company’s investments, through the British Epidarex Fund on October 29, 2024.
Kynos Therapeutics was founded by Dr. Damian Mole and Dr. Scott Webster. It is a biotechnology company focused on developing new inhibitors as an innovative therapeutic approach for acute and chronic inflammatory diseases. This has attracted the attention of Dr. Falk Pharma, a German company that has specialized in the development and marketing of innovative medicines for over 60 years.
In this regard, Dr. Khalid bin Saad Al-Saleh, CEO of Riyadh Valley Company, commented, “Kynos Therapeutics is one of the portfolio companies through the Epidarex Fund of Riyadh Valley Company – the investment arm of King Saud University – which enables this acquisition to continue the efforts of providing a new generation of innovative treatments for acute and chronic inflammatory diseases.”
This acquisition supports the objectives of Riyadh Valley Company – the investment arm of King Saud University – to achieve Saudi Vision 2030 through a balanced investment strategy that leverages local capabilities. The company invests both locally and internationally in early-stage and growth-phase companies to generate financial returns and strategic outcomes that contribute to the growth and development of the knowledge-based economy in Saudi Arabia.
For more information: